#DMAC

StockTitan

@stocktitan.net

1 week ago

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia The Company plans to initiate the trial in 2026 and expand into the United States and United Kingdom as regulatory clearances are obtained. “Health Canada’ s authorization to initiate our Phase 2 clinical trial of DM199 in preeclampsia represents an important regulatory milestone for DiaMedica,” said Rick Pauls, President and Chief Executive Officer of...

#DMAC DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

www.stocktitan.net/news/DMAC/dia-medica-the...

KingFitch 🤴🏿🏀💙🗽🌁🇺🇸🦺

@kingfitch1990.bsky.social

1 month ago

#Jenard #DMAC #RockMusic #PowerForce #Lmao #Music

blaqsbi.com

@blaqsbi.com

2 months ago

Post: #iloveblackwomen #iloveblackwomen

Post: #iloveblackwomen: #iloveblackwomen #Dmac #iloveblackwomen

StockTitan

@stocktitan.net

2 months ago

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA DiaMedica Therapeutics (Nasdaq: DMAC) completed an in-person pre-IND meeting with the FDA for a planned study of DM199 in preeclampsia. The FDA requested one additional non-clinical 10-day modified embryo-fetal development and pre-/postnatal development study in rabbits; DiaMedica has begun preparations and expects results by Q2 2026. The company said meeting minutes provide regulatory clarity as it prepares an IND for early-onset preeclampsia.Separately, an ongoing Phase 2 investigator-sponsored trial in South Africa has dosed >30 women with late-stage PE; interim data reportedly show statistically significant blood pressure reductions, dilation of intrauterine arteries, and no placental transfer of DM199.

#DMAC DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

www.stocktitan.net/news/DMAC/dia-medica-the...

Joe Willmore

@joewillmore.bsky.social

3 months ago

The Des Moines Art Center. I went in with minimal expectations and was instead "wow-ed!" The space is outstanding, the collection and special exhibit great. Buildings/wings by Saarinen, IM Pei, and Meier #DesMoines, #DMAC, #architecture, #art, #IMPei, #saarinen, #Meier,

StockTitan

@stocktitan.net

4 months ago

DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights DiaMedica Therapeutics (Nasdaq: DMAC) reported third quarter 2025 results and a business update on November 12, 2025. Key clinical updates include completion of cohort 10 and initiation of an up-to-12 participant expansion cohort in the Phase 2 IST for preeclampsia (completion of the expansion expected in 1H 2026), screening to begin soon for a Part 3 fetal growth restriction cohort, and an in-person pre-IND meeting with the FDA for U.S. PE plans. Enrollment in the ReMEDy2 Phase 2/3 AIS trial is nearing 50% of the 200-patient interim-analysis target, expected in 2H 2026. Financials: $55.3M cash and short-term investments as of September 30, 2025, with anticipated runway into 2H 2027. Net loss was $24.0M for the nine months ended September 30, 2025.

#DMAC DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

7 months ago

#DMAC DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

7 months ago

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline DiaMedica Therapeutics (Nasdaq: DMAC) has secured a $30.1 million private placement of common shares at $3.50 per share, with participation from current investors. The company will issue 8,606,426 common shares, with the transaction expected to close around July 23, 2025.The funding will support DiaMedica's operations for over two years, focusing on their clinical program for preeclampsia and fetal growth restriction treatments. Key milestones include submitting an IND application in the United States and conducting a Phase 2b study to evaluate DM199 in both indications, pending approval.The private placement qualifies as a related party transaction under Canadian securities regulations but is exempt from valuation and minority shareholder approval requirements as it represents less than 25% of the company's market capitalization.

#DMAC DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

7 months ago

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer DiaMedica Therapeutics (Nasdaq: DMAC) announced positive interim Phase 2 results for DM199 (rinvecalinase alfa) in treating preeclampsia. The study demonstrated statistically significant blood pressure reductions, with the highest dose cohort showing decreases of -35 mmHg in systolic and -15 mmHg in diastolic blood pressure (p<0.05).Key findings include no placental transfer of DM199 and a 13.2% reduction in uterine artery pulsatility index (p=0.0003), suggesting improved placental blood flow. The treatment was generally safe with only mild adverse events reported. The study enrolled patients with mean baseline systolic/diastolic blood pressure of 165/102 mmHg at 37 weeks gestation.The company will proceed with the dose expansion cohort (Part 1b) and initiate enrollment in the fetal growth restriction cohort (Part 3), potentially offering the first pharmacological treatment for preeclampsia in the US and Europe.

#DMAC DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

8 months ago

DiaMedica Joins Russell 2000 and 3000 Indexes as Phase 2 Preeclampsia Results Near Clinical-stage biotech DiaMedica gains Russell indexes membership, boosting institutional exposure. Phase 2 preeclampsia trial results expected mid-July. Get insights.

#DMAC DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

www.stocktitan.net/news/DMAC/dia-medica-the...

@alexvonwitzleben.bsky.social

9 months ago

Restricting the use of chemical substances to protect workers’ health Commission Regulation (EU) amending Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council as regards N,N-dimethylacetamide (DMAC) and 1-ethylpyrrolidin-2-one (NEP)

The Commission has restricted the use of #DMAC and #NEP to protect workers. DMAC is used in making synthetic fibres and varnishes for electrical wires, while NEP is found in cleaning solutions, agrochemicals and construction materials single-market-economy.ec.europa.eu/publications... #chemicals

StockTitan

@stocktitan.net

9 months ago

Groundbreaking Preeclampsia Drug DM199 Under Spotlight: Top Medical Experts Reveal Phase 2 Trial Design Global preeclampsia experts analyze DM199's potential as first-ever treatment. Join live discussion on Phase 2 trial design and breakthrough mechanism of action. Get insights.

#DMAC DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

10 months ago

Major Stroke Treatment Breakthrough: DiaMedica Reveals Phase 2/3 Trial Results at European Stroke Conference Latest clinical outcomes for novel stroke treatment DM199 to be presented at ESOC 2025. Key safety data and efficacy results from pivotal ReMEDy2 trial. Get insights.

#DMAC DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

10 months ago

DiaMedica Nears Crucial Preeclampsia Trial Results: First Treatment Hope for Major Pregnancy Complication Key preeclampsia trial data expected June-July. Phase 2/3 stroke study advancing with $37.3M cash runway. Get insights on DiaMedica's breakthrough treatment potential.

#DMAC DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

www.stocktitan.net/news/DMAC/dia-medica-the...

M 🍂

@laziamatta.bsky.social

11 months ago

DMAC by Anton Corbijn

“And then, a dark period started”

Madrid 1992
#SOFAD #DepecheMode #DMAC

StockTitan

@stocktitan.net

11 months ago

DiaMedica's Dual Clinical Programs Show Progress as Cash Runway Extends to 2026 DiaMedica expands clinical footprint with 30 active sites for stroke therapy and new preeclampsia trial, backed by $44.1M cash runway through Q3 2026. Key data expected 2025-2026.

#DMAC DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

1 year ago

DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke DiaMedica Therapeutics (Nasdaq: DMAC) announced a peer-reviewed publication in the journal Stroke detailing DM199's mechanism of action for treating acute ischemic stroke (AIS). The article, scheduled for print in February 2025, explains how DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1, works as a bradykinin-producing enzyme to enhance collateral circulation and stimulate angiogenesis.The research shows that in acute stroke animal studies, bradykinin B2 receptor expression increased 36-fold on brain endothelial cells in ischemic regions. DM199 generates bradykinin that induces local vasodilation and improves brain perfusion through three synergistic signaling pathways. The treatment's preferential effect on ischemic tissue helps avoid systemic adverse effects like hypotension when properly dosed.The prior Phase 2 ReMEDy1 trial showed favorable clinical outcomes in AIS patients ineligible for mechanical thrombectomy. The mechanism is currently being studied in the ongoing Phase 2/3 ReMEDy2 Trial.

#DMAC DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

www.stocktitan.net/news/DMAC/dia-medica-the...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Small-cap stocks with strong volume gains, Wed Feb 19th - #CVEO #GB #SEDG #QUAD #RCUS #TNC #XYF #ADEA #CDRO #DMAC #EDIT #GMGI #ITRN #MFH #PMVP #SEDG - More: crystalequityresearch.com/SmCpStr/ - #smallcap

M 🍂

@laziamatta.bsky.social

1 year ago

“Halo” video from DM AC

Jenna Elfman on the set of Halo

Ci ho messo del tempo per scoprire questa cosa (per fortuna è una delle canzoni che più amo…)

“The tall one on the right is actress Jenna Elfman who in 1999 received a Golden Globe. 'Halo' was her first role though!”

#DMAC #DepecheMode #AntonCorbijn

M 🍂

@laziamatta.bsky.social

1 year ago

Qualche mese fa mi sono fatta un regalone, un libro TASCHEN che desideravo da anni…

#DMAC #DepecheMode #AntonCorbijn

StockTitan

@stocktitan.net

1 year ago

DiaMedica Forms Elite Scientific Advisory Board for Preeclampsia Treatment Development | DMAC Stock News DiaMedica Therapeutics assembles world-renowned experts to advance DM199, its promising preeclampsia treatment. Leading specialists join forces to tackle this critical maternal health condition.

#DMAC DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

#StockMarket #news #investing

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

1 year ago

#DMAC DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results

www.stocktitan.net/news/DMAC/dia-medica-the...

StockTitan

@stocktitan.net

1 year ago

#DMAC DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia

www.stocktitan.net/news/DMAC/dia-medica-the...

Market Wire News

@marketwirenews.com

1 year ago

News; ( NASDAQ: #DMAC ) DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024

#StockMarket #News

Market Wire News

@marketwirenews.com

1 year ago

Breaking News: ( NASDAQ: #DMAC ) DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

#StockMarket #News